Cross-resistance of isoniazid, para-aminosalicylic acid and pasiniazid against isoniazid-resistant Mycobacterium tuberculosis isolates in China
ConclusionTaken together, these results demonstrate that PAS resistance and mutations in thekatG gene, inhA promoter or oxyR–ahpC intergenic region in INH-resistant M. tuberculosis have little effect on pasiniazid susceptibility.
Mycobacterium tuberculosis is the leading cause of death from bacterial infection. Improved rapid diagnosis and antimicrobial resistance determination, such as by whole-genome sequencing, are required. Our aim was to develop a simple, low-cost method of preparing DNA for sequencing direct from M. tuberculosis-positive clinical samples (without culture). Simultaneous sputum liquefaction, bacteria heat inactivation (99°C/30 min), and enrichment for mycobacteria DNA were achieved using an equal volume of thermo-protection buffer (4 M KCl, 0.05 M HEPES buffer, pH 7.5, 0.1% dithiothreitol [DTT]). The buffer emulated intrace...
Publication date: Available online 18 September 2020Source: Journal of Global Antimicrobial ResistanceAuthor(s): Alper Karagoz, Hidayet Tutun, Levent Altintas, Umit Alanbayi, Dilara Yildirim, Nadir Kocak
Tuberculosis (TB) is one of the major causes of death related to antimicrobial resistance worldwide because of the spread of Mycobacterium tuberculosis multi- and extensively drug resistant (multi-drug resistant (MDR) and extensively drug-resistant (XDR), respectively) clinical isolates. To fight MDR and XDR tuberculosis, three new antitubercular drugs, bedaquiline (BDQ), delamanid, and pretomanid were approved for use in clinical setting. Unfortunately, BDQ quickly acquired two main mechanisms of resistance, consisting in mutations in either atpE gene, encoding the target, or in Rv0678, coding for the repressor of the Mmp...
Publication date: September 2020Source: Journal of Global Antimicrobial Resistance, Volume 22Author(s): Yan Shao, Yishu Li, Honghuan Song, Guoli Li, Yan Li, Limei Zhu, Wei Lu, Cheng Chen
Publication date: August 2020Source: The Lancet Global Health, Volume 8, Issue 8Author(s): Gwenan M Knight, Mario C Raviglione, Richard G White
GENEVA, SWITZERLAND, 6 JULY 2020 – The Stop TB Partnership and Johnson &Johnson – with support from the Global Fund to Fight AIDS, TB and Malaria, and the U.S. Agency for International Development (USAID) – today announced joint efforts to help enable low- and middle-income countries to rapidly scale up use of SIRTURO® (bedaquiline) 100mg tablets in support of new, recently-released World Health Organization (WHO) treatment guidelines. Effective immediately, Johnson &Johnson will make bedaquiline available to Stop TB Partnership’s Global Drug Facility (GDF) at a price of USD$340 per six-...
Publication date: September 2020Source: Journal of Global Antimicrobial Resistance, Volume 22Author(s): Ayush Lohiya, Rizwan Suliankatchi Abdulkader, Rama Shankar Rath, Olivia Jacob, Palanivel Chinnakali, Akhil Dhanesh Goel, Sumita Agrawal
Publication date: September 2020Source: Journal of Global Antimicrobial Resistance, Volume 22Author(s): Eddie S. Solo, Chie Nakajima, Trevor Kaile, Precious Bwalya, Grace Mbulo, Yukari Fukushima, Sylvia Chila, Nanthan Kapata, Yogendra Shah, Yasuhiko Suzuki
Publication date: September 2020Source: Journal of Global Antimicrobial Resistance, Volume 22Author(s): Ibrahim Bitar, Matej Medvecky, Jana Amlerova, Costas C. Papagiannitsis, Jaroslav Hrabak
Publication date: September 2020Source: Journal of Global Antimicrobial Resistance, Volume 22Author(s): Divakar Sharma, Sandeep Sharma, Juhi Sharma